What is Pharming Group N.V.'s (PHAR) StockRank?

MoatMap's StockRank for Pharming Group N.V. (PHAR) is 55/100, with a Hold signal. This is a composite score combining Quality (67), Value (38), and Momentum (43) factor ranks across MoatMap's 20,000+ stock universe.

Does Pharming Group N.V. have an economic moat?

Pharming Group N.V. (PHAR) has a Quality factor score of 67/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Pharming Group N.V. a buy, hold, or sell?

MoatMap's current signal for Pharming Group N.V. (PHAR) is Hold, based on a StockRank of 55/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Pharming Group N.V. in?

Pharming Group N.V. (PHAR) operates in the Healthcare sector, specifically the Biotechnology industry (Netherlands).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PHAR

Hold

Pharming Group N.V. · Healthcare · Netherlands · $828M · Avg Vol: $233K/d

StockRank

Get insider-trade alerts

P/E (TTM)

85.4x

ROE

3.6%

D/E

0.4x

Dividend %

—

COMPANY DESCRIPTION

Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing innovative products for rare diseases, with its lead product, Ruconest, treating hereditary angioedema (HAE). Specializing in orphan drugs, the company benefits from smaller, well-defined patient populations and often faster regulatory pathways, with Ruconest holding market exclusivity in certain regions. Pharming is a niche player in the rare disease biotechnology space, concentrating on therapies for specific patient populations.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	205.6M	245.3M	297.2M	376.1M	22.3%	366.5M	382.8M	424.9M	6.3%
EPS	1.95	-1.43	-1.54	0.40	-41.2%	0.14	0.46	0.31	-12.1%
Shares	70.6M	70.6M	70.6M	70.6M	0.0%	70.8M	—	—	—
Debt	166.7M	171.5M	112.3M	115.8M	-11.4%	113.3M	—	—	—
Equity	204.6M	218.8M	221.1M	277.1M	10.6%	—	—	—	—
Op CF	22.5M	-17.3M	-1.8M	54.7M	34.6%	35.0M	—	—	—
Inv CF	5.3M	-129.4M	31.6M	26.3M	—	—	—	—	—
Fin CF	-5.0M	-1.0M	-34.4M	1.5M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-10.8%

SMA 50SMA 200

$11.70

RSI (14)

54.2

52W High

$21.34

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

6.1%61.3

ROE

3.6%54.1

GP/Assets

63.4%92.0

Op. Margin

1.5%47.5

FCF/Assets

11.8%89.3

Piotroski

784.2

Int. Cover

2.2x44.4

D/E Ratio

0.42x34.0

Current Ratio

3.01x54.2

Value

P/E (TTM)

85.4x10.8

EV/EBITDA

24.4x24.9

P/FCF

14.0x73.2

P/B

3.1x43.0

P/S

2.3x64.7

Div Yield

—N/A

Momentum

52W High %

55%28.3

RS 6M

-41%21.2

SMA 50/200

0.82x22.0

EPS Rev 4W

+368.7%100.0

EPS Rev 12W

+5.7%81.6

EPS Improve

+119%78.7

Q Growth

-65%6.6

FUNDAMENTALS

Market Cap

$828M

P/E (Forward)

38.9x

Gross Margin

86.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHAR are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
PHAR	Pharming Group N.V.(you)	$828M	55	Hold
PRQR	ProQR Therapeutics N.V.	$323M	30	Sell
QURE	uniQure N.V.	$3.4B	18	Strong Sell
NAMS	NewAmsterdam Pharma Company N.V.	$3.0B	9	Strong Sell
ONWD.BR	Onward Medical N.V.	$199M	4	Strong Sell
ARGX	argenx SE	$63.6B	75	Buy
RDC.DE	Redcare Pharmacy NV	$1.5B	54	Hold
QGEN	Qiagen N.V.	$8.9B	65	Buy
PHG	Koninklijke Philips N.V.	$26.1B	84	Strong Buy

Peer medians: ROE 10.2% · P/E 22.0x · Gross margin 62.7%

Price	$11.70
Market Cap	$828M
P/E (TTM)	85.36
P/E (Forward)	38.93
Price/Book	3.13
Return on Equity	3.6%
Return on Invested Capital	6.1%
Debt/Equity	0.42x
Gross Margin	86.5%
Operating Margin	1.5%
Revenue Growth	-3.2%
Free Cash Flow	$59M